Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Current Assets (2021 - 2025)

Amylyx Pharmaceuticals (AMLX) has 5 years of Current Assets data on record, last reported at $323.7 million in Q4 2025.

  • For Q4 2025, Current Assets rose 70.86% year-over-year to $323.7 million; the TTM value through Dec 2025 reached $323.7 million, up 70.86%, while the annual FY2025 figure was $323.7 million, 70.86% up from the prior year.
  • Current Assets reached $323.7 million in Q4 2025 per AMLX's latest filing, down from $353.4 million in the prior quarter.
  • Across five years, Current Assets topped out at $464.7 million in Q4 2023 and bottomed at $105.0 million in Q4 2021.
  • Average Current Assets over 5 years is $300.5 million, with a median of $323.7 million recorded in 2025.
  • Peak YoY movement for Current Assets: skyrocketed 264.11% in 2022, then crashed 59.23% in 2024.
  • A 5-year view of Current Assets shows it stood at $105.0 million in 2021, then surged by 264.11% to $382.1 million in 2022, then grew by 21.6% to $464.7 million in 2023, then plummeted by 59.23% to $189.4 million in 2024, then surged by 70.86% to $323.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Assets were $323.7 million in Q4 2025, $353.4 million in Q3 2025, and $186.9 million in Q2 2025.